Affirm partners with Ant International’s Antom to offer pay-over-time at US checkouts
Bitget2026/10/06 13:02Affirm partnered with Ant International’s Antom to offer its pay-over-time option to Antom merchants in the US. Antom merchants can add Affirm at checkout via Antom’s portal, expanding Affirm’s distribution across Antom’s US merchant base. Approved customers can access financing for purchases from $35 to $30,000, with terms from 30 days to 36 months. Rollout to UK customers is planned within this year, with broader international expansion under consideration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Affirm Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261006162957) on October 06, 2026, and is solely responsible for the information contained therein.
- Affirm partnered with Ant International’s Antom to offer its pay-over-time option to Antom merchants in the US.
- Antom merchants can add Affirm at checkout via Antom’s portal, expanding Affirm’s distribution across Antom’s US merchant base.
- Approved customers can access financing for purchases from $35 to $30,000, with terms from 30 days to 36 months.
- Rollout to UK customers is planned within this year, with broader international expansion under consideration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.